T-3775440,1422535-52-1

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

T-3775440 hydrochloride

CAS No. : 1422535-52-1

MCE 国际站：T-3775440 hydrochloride

产品活性：T-3775440 (hydrochloride) 是一种赖氨酸特异性脱甲基酶1 (LSD1) 的不可逆性抑制剂，其 IC₅₀ 值为 2.1 nM。

研究领域：Epigenetics

作用靶点：Histone Demethylase

In Vitro: T-3775440 demonstrates irreversible inhibition of recombinant human LSD1, with a kinact/KI value of 1.7×10⁵ (sec⁻¹ M⁻¹). T-3775440 is highly selective for LSD1 relative to other monoamine oxidases (e.g., MAO-A and MAO-B), with an IC₅₀ value of 2.1 nM). T-3775440 blocks the proliferation of several cell lines as quickly as day 3 of treatment. Notably, the granulocyte/macrophage markers CD86 and CD11b are commonly upregulated on both TF-1a and HEL92.1.7 cells in response to T-3775440 treatment, whereas the erythroid markers CD235a and CD71 are downregulated by this treatment. In CMK11-5 cells, CD86 mRNA expression is also clearly upregulated by T-3775440 in a concentration-dependent manner, although only a modest increase in cell surface CD86 expression is observed. T-3775440 treatment disrupts the LSD1-GFI1B association in a concentration-dependent manner. T-3775440 decreases LSD1 binding but not GFI1B binding and increases the level of dimethylated H3K4 at the PI16 locus.

In Vivo: T-3775440 upregulates CD86 mRNA expression in tumor xenografts of HEL92.1.7 cells in a dose-dependent manner following the oral administration of single doses ranging from 3 to 30 mg/kg. To investigate target engagement of this compound in tumors, PI16 expression levels is tested as a direct biomarker. As expected, PI16 suppression is dramatically reversed by T-3775440 treatment. In a TF-1a (AEL) tumor xenograft model, T-3775440 exhibits significant antitumor effects, with 15-day T/C values of 15.6% and <0% at doses of 20 and 40 mg/kg, respectively. T-3775440 also exhibits potent antitumor effects in an additional AEL model of HEL 92.1.7 and an AMKL model of CMK11-5, leading to nearly complete tumor growth suppression during the dosing period. It is found that in mice, T-3775440 treatment results in a transient reduction in platelets, followed by a significant rebound; this is considered a mechanism-based adverse effect of LSD1 inhibition. On a dosing schedule comprising 5 days on/2 days off, a statistically significant difference in body weight is observed between vehicle- and T-3775440–treated tumor xenograft model mice at higher doses. However, efficacious T-3775440 doses are tolerated in all subcutaneous tumor xenograft models.

相关产品：Covalent Screening Library Plus  |  Bioactive Compound Library Plus  |  Epigenetics Compound Library  |  Histone Modification Research Compound Library  |  Anti-Cancer Compound Library  |  Covalent Screening Library  |  Anti-Cancer Metabolism Compound Library  |  Targeted Diversity Library  |  Heterocyclic Compound Library  |  Highly Selective Inhibitors Library  |  GSK-J4  |  Eicosapentaenoic Acid  |  IOX1  |  JIB-04  |  CPI-455  |  Iadademstat dihydrochloride  |  Tranylcypromine hemisulfate  |  KDM5-C70  |  SP2509  |  QC6352  |  GSK2879552  |  GSK-LSD1 dihydrochloride  |  Pulrodemstat benzenesulfonate  |  AS8351  |  Seclidemstat  |  KDOAM-25 citrate  |  Daminozide  |  ML324  |  NCGC00244536  |  Corin  |  GSK467  |  KDM5A-IN-1  |  PFI-90  |  KDM2A/7A-IN-1  |  L-2-Hydroxyglutaric acid disodium  |  Procaine  |  SKLB325

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds